NCT05107037 - A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis | Biotech Hunter

Enrollment

120

Participants

Timeline

Start Date

November 30, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions

Type I Neurofibromatosis

Interventions

DRUG

TQ-B3234 capsule

TQ-B3234 is an anti-tumor molecular targeted drug, which is a selective Mitogen-activated protein kinase kinase（MEK）1/2 inhibitor

Trial Locations (1)

Shanghai Ninth People's Hospital ，Shanghai JiaoTong University School of Medicine, Shanghai